Search research articles
Contact Us
Filters
Showing results (321-330 of 353) with videos related to
Page
of 36
Sort By:
European Urology
|
September 8, 2021
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
Edmond M Kwan, Lavinia Spain, Angelyn Anton, et al.
The Lancet. Oncology
|
November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Lancet. Oncology
|
June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
European Urology
|
December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial
Shankar Siva, Mathias Bressel, Simon T Wood, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)
|
June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
David C Chen, James P Buteau, Nathan Papa, et al.
Page
of 36
Search research articles
Search
Showing results (321-330 of 353) with videos related to
Sort By:
Page
of 36
European Urology
|
September 8, 2021
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
Edmond M Kwan, Lavinia Spain, Angelyn Anton, et al.
The Lancet. Oncology
|
November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Future Oncology (London, England)
|
June 4, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2025
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
The Lancet. Oncology
|
June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
European Urology
|
December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial
Shankar Siva, Mathias Bressel, Simon T Wood, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Arun A Azad, Karim Fizazi, Nobuaki Matsubara, et al.
Lancet (London, England)
|
July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)
|
June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
David C Chen, James P Buteau, Nathan Papa, et al.
Page
of 36